Non Muscle Invasive Bladder Cancer (NMIBC)-Clinical Trial Insight
- September 2020
- 90 pages
Non Muscle Invasive Bladder Cancer Understanding
Non Muscle Invasive Bladder Cancer: Overview
NMIBC is defined as a superficial neoplasia confined to the mucosa, (including Ta which is a noninvasive papillary carcinoma and carcinoma in situ (CIS), which is flat and non-papillary) or lamina propria (T1) based on the American Joint Committee on Cancer (AJCC) staging system, also known as the tumor node metastases (TNM) classification. Ta accounts for most NMIBC (60%), whereas T1 and Tis (CIS) account for 30% and 10%, respectively.
Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
Hematuria (blood in the urine) - the most common symptom, often without pain
Frequent and urgent urination
Pain when urine passes
Pain in lower abdomen
The following tests may be done to determine bladder cancer:
Urine cytology: The color and content of the urine will be checked. This test will also look at body cells under a microscope.to test for cancer cells.
Blood tests: A comprehensive metabolic panel (CMP), which includes kidney and liver function tests
A. Computerized tomography scan (also known as CT or CAT scans) with a bladder scope "cystoscopy" are often good enough to diagnose bladder cancer.
Cystoscopy: A doctor will use a thin tube that has a light and camera at the end of it (cystoscope) to pass through the urethra into the bladder.
The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy. Pembrolizumab is approved for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy
Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters
This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Non Muscle Invasive Bladder Cancer Emerging Drugs
Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the bodys own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. By harnessing the bodys own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. It is currently in phase III stage of development.
UGN-102: UroGen Pharma
UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC.Administered locally via standard catheters, UGN-102 is designed to fill and conform to the anatomy of the bladder and dwell for a period of several hours before being excreted via normal urine flow. UroGen has completed enrollment in a phase 2b study to further investigate UGN-102 for the treatment of intermediate-risk low-grade NMIBC.
Further product details are provided in the report..
Non Muscle Invasive Bladder Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Non-Muscle Invasive Bladder Cancer
There are approx. 25+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. phase III include, Bristol-Myers Squibb/Ono Pharmaceuticals.
DelveInsights report covers around 30+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Non Muscle Invasive Bladder Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.
In July 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical had signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.
In April 2020, UroGen Pharma announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). These data were featured in a late-breaking abstract published in the April Supplement to The Journal of Urology. The detailed results presentation will be available online via the American Urological Association (AUA) in mid-May 2020.
Non Muscle Invasive Bladder Cancer Report Insights
Non Muscle Invasive Bladder Cancer Pipeline Analysis
Impact of Drugs
Non Muscle Invasive Bladder Cancer Report Assessment
Pipeline Product Profiles
Inactive drugs assessment
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Non Muscle Invasive Bladder Cancer drugs?
How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?
What are the key designations that have been granted to the emerging drugs?
UroGen Pharma Ltd.
Merck Sharp & Dohme Corp.
Jiangsu Yahong Meditech Co.,Ltd.
Janssen Research & Development, LLC
Hamlet Pharma AB
H3 Biomedicine Inc.
CG Oncology, Inc.
Bioniche Life Sciences Inc.
Bladder Cancer Program
Have query on this report?Make an Enquiry
Non Muscle Invasive Bladder Cancer: Overview
Mechanism of Action
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Oncology
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017